The effect of dextromethorphan on the severity of symptoms in patients with OCD

Phase 3

Conditions: obsessive-compulsive disorder.
Obsessive-compulsive disorder

Registration Number: IRCT20120520009801N6

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 72

Inclusion Criteria

OCD patients who have been treated with high doses of SSRI for at least 8 weeks but have a Y-BOCS index score higher than 15. (High doses of SSRI includ: Sertraline 200mg/day, Paroxetine 60mg/day, Fluoxetine 80mg/day and Fluvoxamine mg/day)
subjects aged 18 to 60 years
Obtaining the patient's informed consent

Exclusion Criteria

Pregnancy or breastfeeding
Using serotonergic drugs other than SSRIs
Use of NMDA receptor antagonists other than dextromethorphan and memantine
Psychotic and bipolar disorders (based on DSM-5 criteria)
Liver dysfunction (LFT> 3ULN)
Kidney dysfunction (GFR <60 ml / kg / min)
Thyroid Disorders (Based on Thyroid Function Test)
History of seizures

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of the effect of dextromethorphan in comparison with placebo on reducing the severity of symptoms in patients with obsessive-compulsive disorder based on (Y-BOCS) YALE-BROWN OBSESSIVE COMPULSIVE SCALE. Timepoint: Before intervention and 1 month, 2 months and 3 months after intervention. Method of measurement: Yale–Brown Obsessive Compulsive Scale.

Secondary Outcome Measures

Name	Time	Method
Comparison of quantitative electroencephalographic (QEEG) changes in different groups. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Quantitative Electroencephalogram.;Comparison of changes in executive functions in different groups. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Delis-Kaplan Executive Function System (D-KEFS) tests.